How Much Does Oral Micronized Progesterone Cost in New York in 2026?

New York Retail Pricing for Oral Micronized Progesterone

The average cash-pay price for generic oral micronized progesterone across New York retail pharmacies sits at approximately $45 per month in 2026. Brand-name Prometrium, manufactured originally by Solvay (now AbbVie), lists at $180 per month, though few patients pay this amount out of pocket.

Price variation across the state is significant. Manhattan pharmacies in high-rent districts may charge $55-65 for a 30-day supply of generic 100 mg capsules, while pharmacies in Buffalo, Rochester, or suburban Long Island often price closer to $35-40. Chain pharmacies like CVS, Walgreens, and Rite Aid maintain relatively consistent pricing within a $10 range, while independent pharmacies may offer lower cash prices to compete.

The PEPI Trial (Postmenopausal Estrogen/Progestin Interventions, N=875) established oral micronized progesterone as an effective alternative to medroxyprogesterone acetate for endometrial protection, demonstrating equivalent prevention of endometrial hyperplasia with a more favorable lipid profile 1. This evidence base supports the clinical rationale behind insurance coverage decisions in New York.

For patients filling 200 mg capsules (the standard dose for cyclic endometrial protection), expect to pay roughly 15-20% more than the 100 mg price, as most pharmacies price by capsule count rather than total milligrams dispensed.

New York Medicaid Coverage

New York Medicaid covers oral micronized progesterone for endometrial protection during hormone replacement therapy, though prior authorization is required. The PA process typically takes 48-72 hours through the state's eMedNY system.

To obtain prior authorization, prescribers must document that the patient is receiving concurrent estrogen therapy and has an intact uterus. The 2022 North American Menopause Society position statement recommends progesterone co-administration for all women with a uterus using systemic estrogen, stating that "the addition of a progestogen is recommended to reduce the risk of endometrial cancer" 2. New York Medicaid aligns with this guidance.

Managed Medicaid plans in New York (Fidelis Care, Healthfirst, MetroPlus, Molina, Amerigroup) may have slightly different formulary placements. Most list generic oral micronized progesterone on Tier 1 with a $0-3 copay after PA approval. Patients enrolled in the Essential Plan, which covers individuals earning up to 200% of the federal poverty level, face similar formulary access with minimal cost-sharing.

Denial rates for oral micronized progesterone PA in New York Medicaid run lower than for many other hormone therapies. The most common denial reason is missing documentation of concurrent estrogen use, which prescribers can resolve by resubmitting with chart notes confirming the HRT regimen.

Insurance Coverage on Commercial Plans

Most commercial insurance plans operating in New York place generic oral micronized progesterone on Tier 1 or Tier 2 of their formularies. Typical copays range from $5-15 for a 30-day supply through major carriers including UnitedHealthcare, Aetna, Empire Blue Cross, Cigna, and Oscar Health.

The Endocrine Society's 2022 clinical practice guideline on menopausal hormone therapy reinforces that micronized progesterone is the preferred progestogen for most women, citing "a potentially lower risk of breast cancer and venous thromboembolism compared with synthetic progestins" 3. This guideline support means insurance medical directors rarely challenge coverage for FDA-approved indications.

Brand Prometrium may require step therapy (trying generic first) or carry a Tier 3 copay of $35-60 on many plans. Since the generic is pharmaceutically equivalent, most patients and physicians accept generic substitution without clinical concern.

New York's insurance regulations under the Women's Health and Wellness Act mandate coverage of FDA-approved contraceptives without cost-sharing, but this does not directly apply to progesterone prescribed for HRT. Patients using oral micronized progesterone solely for menopausal endometrial protection will still face standard formulary cost-sharing unless their plan offers enhanced menopause benefits.

Compounded Progesterone in New York

Compounded oral micronized progesterone from licensed 503A pharmacies costs approximately $25 per month in New York. This option is legal under strict New York State Board of Pharmacy oversight.

Section 6808 of New York Education Law permits pharmacies to compound medications pursuant to a valid prescription for an individual patient when a commercially available product does not meet the patient's specific needs. Common clinical justifications include peanut oil allergy (the commercial product uses peanut oil as its suspension medium), need for non-standard doses, or requirement for dye-free formulations.

The New York State Board of Pharmacy conducts regular inspections of 503A compounding pharmacies. These facilities must comply with USP <795> standards for non-sterile compounding and maintain detailed beyond-use dating records. Patients should verify their compounding pharmacy holds current New York licensure through the Office of the Professions online verification system.

Dr. JoAnn Pinkerton, former executive director of the North American Menopause Society, has noted that "while FDA-approved formulations should be first-line, compounded bioidentical hormones may be appropriate when patients cannot use commercially available products due to allergies or require individualized dosing" 4.

One caveat: compounded progesterone is not AB-rated as equivalent to Prometrium. Dissolution characteristics and bioavailability may differ between compounding pharmacies. Insurance plans, including Medicaid, typically do not cover compounded hormones.

Discount Programs and Savings Strategies

Several pathways exist to reduce oral micronized progesterone costs below standard retail pricing in New York. GoodRx, RxSaver, and similar discount card platforms frequently offer generic oral micronized progesterone for $15-25 at participating New York pharmacies.

The manufacturer savings card for brand Prometrium (now administered through AbbVie's patient access programs) can reduce brand copays to $25-35 for commercially insured patients. This card does not apply to government insurance (Medicare, Medicaid, Tricare). Eligibility requires active commercial insurance coverage with a Prometrium prescription.

Mark Cuban Cost Plus Drugs offers generic oral micronized progesterone at a transparent markup over acquisition cost, typically pricing 30 capsules of 100 mg at $8-12 before shipping. This mail-order option ships to New York addresses and bypasses traditional pharmacy benefit manager pricing structures.

For uninsured patients, several strategies stack:

Costco pharmacies in New York (membership not required for pharmacy services in New York state) price generic progesterone competitively, often $30-35 for a 30-day supply. Combining a GoodRx coupon at independent pharmacies sometimes beats even this price.

The Rx Outreach program and NeedyMeds database list additional patient assistance options for patients earning below 300% of the federal poverty level.

Telehealth Prescribing in New York

Oral micronized progesterone is legally prescribable via telehealth in New York without geographic restriction within the state. The 2023 permanent telehealth parity legislation (Chapter 579, Laws of 2023) cemented audio-video and audio-only prescribing authority that originated during the COVID-19 public health emergency.

New York-licensed physicians, nurse practitioners, and physician assistants may prescribe oral micronized progesterone after conducting an appropriate clinical evaluation via telehealth. No in-person visit is required for initial prescribing or ongoing management, though clinicians must exercise standard clinical judgment regarding when physical examination is necessary.

Several telehealth platforms operating in New York specialize in menopause care and HRT prescribing. These services typically charge $100-200 for an initial consultation and $50-100 for follow-up visits, with the progesterone prescription filled separately through the patient's chosen pharmacy.

The FDA label for oral micronized progesterone specifies its approved indication as "prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogens tablets" 5. Off-label uses, including luteal phase support, sleep improvement, and anxiety reduction, are also commonly prescribed via telehealth in New York, though insurance coverage for off-label indications may require additional documentation.

Price Comparison: Brand vs. Generic vs. Compounded

Understanding the three-tier pricing structure helps New York patients make informed decisions about their progesterone source. The cost differential is substantial enough to warrant discussion with prescribers.

Brand Prometrium at $180 per month represents the ceiling. The FDA approved generic oral micronized progesterone in 1998, and multiple manufacturers (Teva, Mylan/Viatris, Sun Pharma, Virtus) now produce it. All generics must meet FDA bioequivalence standards, demonstrating plasma progesterone levels within 80-125% of the reference listed drug.

A 2020 systematic review published in Menopause found no clinically meaningful difference in endometrial outcomes between brand and generic oral micronized progesterone formulations 6. The review examined data from over 3,000 patients across multiple studies and confirmed equivalent endometrial protection.

Generic at $45 per month represents the standard retail cash price. With discount cards, this drops to $15-25. Through Cost Plus Drugs or select pharmacy programs, it can reach $8-12 plus shipping.

Compounded at $25 per month fills a specific niche: patients with documented peanut oil allergies, those requiring custom doses (50 mg, 75 mg, 150 mg, or vaginal preparations), or patients needing capsules without specific inactive ingredients. The trade-off is less regulatory oversight of final product quality compared to FDA-approved generics, and no insurance reimbursement.

Annual Cost Projections for New York Patients

Annualized, the financial picture varies dramatically by coverage status. A commercially insured patient on a Tier 1 generic pays approximately $60-180 per year in copays. A Medicaid patient with approved PA pays $0-36 annually.

An uninsured patient paying full retail faces $540 per year for generic, reducible to $180-300 with discount cards. Choosing compounded progesterone brings the annual cost to approximately $300 without discounts.

The Women's Health Initiative (WHI) demonstrated that continuous combined estrogen-progestin therapy using medroxyprogesterone acetate carried specific risks, but the observational E3N cohort study (N=80,377) found that oral micronized progesterone combined with transdermal estradiol showed no increased breast cancer risk over a mean follow-up of 8.1 years (RR 1.00 to 95% CI 0.83-1.22) 7. This safety profile supports long-term use patterns that make annual cost projections clinically relevant for many New York patients planning multi-year HRT.

For patients anticipating 5-10 years of progesterone use (typical for women beginning HRT in their early 50s), the cumulative savings from choosing generic over brand amount to $8,100-16,200. Choosing compounded over brand saves $9,300-18,600 over a decade, though this calculation excludes the cost of the required prescription and any monitoring labs.

How New York Compares to Neighboring States

New York's average generic cash price of $45 per month falls mid-range for the Northeast. New Jersey averages $42-48, Connecticut $47-52, and Pennsylvania $38-44. Massachusetts, with its strong Medicaid program (MassHealth), offers equivalent PA-based coverage.

New York's advantage lies in its broad Medicaid expansion coverage (up to 138% FPL for standard Medicaid, up to 200% FPL for the Essential Plan) and its large number of licensed 503A compounding pharmacies concentrated in the New York City metropolitan area. Patients in rural upstate New York may have fewer compounding pharmacy options within driving distance, making mail-order compounding or standard generic dispensing more practical.

The New York State Department of Financial Services requires insurers to maintain adequate pharmacy networks, ensuring that oral micronized progesterone remains accessible regardless of geographic location within the state. Patients in all 62 counties can access this medication through at least one in-network pharmacy within their plan's network adequacy standards.